Sindrom Klinefelter

01Pathophysiology

Klinefelter syndrome results from meiotic nondisjunction during gametogenesis, leaving the male zygote with at least one extra X chromosome. The most common karyotype is 47,XXY, accounting for roughly 80 to 90 percent of cases. Nondisjunction is maternal in origin in about half of cases, explaining the link with advanced maternal age. The remaining cases arise from paternal nondisjunction or post-zygotic mitotic errors that produce mosaic forms (46,XY/47,XXY), which often have a milder phenotype.

The extra X chromosome causes progressive seminiferous tubule hyalinization and fibrosis, beginning in mid-puberty. Sertoli and Leydig cell function declines, leading to azoospermia and androgen deficiency. Because the gonads fail at the level of the testis, the pituitary loses negative feedback, and FSH and LH rise dramatically. This is the textbook picture of primary (hypergonadotropic) hypogonadism.

Androgen deficiency during puberty explains the clinical phenotype. Without adequate testosterone, epiphyseal plates remain open longer, producing disproportionately long lower extremities and the eunuchoid habitus (arm span greater than height by more than 2 cm; lower body segment longer than upper). Reduced androgen action also causes sparse facial and pubic hair, decreased muscle bulk, and small phallus development. The relative excess of estrogen, generated by peripheral aromatization of weak androgens combined with Leydig cell dysfunction, drives gynecomastia.

The supernumerary X also contributes to neurocognitive features. Genes that escape X-inactivation (in the pseudoautosomal regions) produce a gene-dosage effect, which is linked to mild language-based learning difficulties, reduced verbal IQ, and increased rates of attention problems. Importantly, the great majority of affected men have normal intelligence.

A clinically important consequence is the elevated lifetime risk of breast cancer (roughly 20 to 50 times that of the general male population), mediastinal germ cell tumors, osteoporosis, metabolic syndrome, and autoimmune disease, all linked to the abnormal hormonal milieu and chromosomal background.

02Classification and Clinical Manifestations

03Diagnostic Workup

The workup begins when a clinician encounters a tall adolescent or young man with small firm testes, gynecomastia, or unexplained infertility. The best initial step is a hormonal panel measuring FSH, LH, and total testosterone in the early morning. The hallmark biochemical pattern is primary hypogonadism: markedly elevated gonadotropins with low or low-normal testosterone. Semen analysis typically reveals azoospermia, which is the most common reason for adult diagnosis (the condition is identified during a fertility workup in a substantial fraction of cases).

The most accurate, confirmatory test is the peripheral blood karyotype, demonstrating 47,XXY. If mosaicism is suspected and the standard karyotype is negative despite a strong clinical picture, additional cells should be analyzed, or fluorescence in situ hybridization (FISH) on buccal mucosa or skin fibroblasts can be used.

After diagnosis, baseline assessment should include a DEXA scan, fasting glucose and lipid profile, thyroid function tests, and a clinical breast examination. Imaging is reserved for asymmetric or rapidly enlarging breast tissue, given the elevated breast cancer risk. Mediastinal imaging is not routine but should be pursued if symptoms suggest a germ cell tumor.

04Management and Treatment

Management hinges on testosterone replacement therapy (TRT), ideally initiated at the start of puberty when biochemical hypogonadism becomes apparent, or at diagnosis in adults with low testosterone. Common regimens include testosterone cypionate or enanthate 50 to 100 mg intramuscularly every 1 to 2 weeks in adolescents, increasing to adult doses of 100 to 200 mg every 1 to 2 weeks, or transdermal preparations dosed daily. Long-acting injectable testosterone undecanoate ($10001000$ mg every 10 to 14 weeks after loading) is also used. The aim is to restore secondary sexual characteristics, support bone density and muscle mass, and improve mood, libido, and metabolic parameters.

TRT should be monitored every 3 to 6 months initially with serum testosterone (target mid-normal range), hematocrit, prostate-specific antigen in older patients, and lipid profile. Contraindications include known prostate or breast cancer, untreated severe sleep apnea, erythrocytosis (hematocrit $>54\mathrm{\%}>\; 54\backslash \%$), and uncontrolled heart failure. Importantly, testosterone therapy does not restore fertility; in fact, exogenous testosterone suppresses any residual spermatogenesis, so men who wish to father children should pursue sperm retrieval before starting TRT or after a washout period.

For fertility, the standard approach is microdissection testicular sperm extraction (microTESE) combined with ICSI, which retrieves sperm in roughly 40 to 50 percent of patients. Outcomes are better when performed in younger men, since seminiferous tubule fibrosis worsens with age. Counseling should address the option of donor sperm or adoption.

The next best step when an adolescent presents with the classic phenotype and laboratory findings consistent with primary hypogonadism is to order a karyotype before initiating long-term testosterone, both to confirm the diagnosis and to provide accurate genetic counseling.

Long-term care includes lifestyle interventions for metabolic syndrome, bone density monitoring, annual breast examination, and psychosocial support for issues including depression, social anxiety, and reduced quality of life that can accompany the diagnosis.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get this question wrong is by anchoring on tall stature alone and choosing Marfan syndrome, or by missing the diagnosis when the vignette emphasizes infertility in an otherwise healthy adult man. The decisive feature is the combination of small, firm testes with elevated FSH and LH and low testosterone. Whenever you see a tall adolescent or young man with gynecomastia plus disproportionately small testes, the test writer is steering you toward Klinefelter syndrome, even if intellectual function is described as normal.

A second common trap is confusing primary versus secondary hypogonadism. Klinefelter is a primary (hypergonadotropic) hypogonadism, so gonadotropins are high. If FSH and LH are low, the answer is hypothalamic-pituitary disease, often Kallmann syndrome. Another classic distractor is fragile X, which also presents with tall stature and learning difficulty but features macroorchidism, the opposite of Klinefelter.

Remember that karyotype is the gold standard, not hormone testing. Hormones support the diagnosis but cannot confirm the chromosomal abnormality. Also remember that testosterone therapy does not treat infertility and will worsen it; sperm retrieval should be considered before TRT in men who want biological children.

The core competencies being tested are: recognizing the classic phenotype (tall, small firm testes, gynecomastia, infertility), interpreting the hormonal pattern of primary hypogonadism, selecting karyotype as the confirmatory test, counseling about lifelong testosterone replacement and its effect on fertility, and maintaining surveillance for the associated comorbidities, particularly breast cancer, osteoporosis, metabolic syndrome, and mediastinal germ cell tumors.